Mutant human CD80 and compositions for and methods of making and using the same
Improved vaccines and methods of using the same are disclosed Immunosuppressive compositions for treating individuals who have autoimmune diseases or transplants and methods of using the same are disclosed.
1. A method immunizing an individual against an immunogen comprising administering a composition comprising
a) a nucleic acid sequence comprising a human CD80 mutant protein coding sequence operably linked to regulatory elements, wherein said human CD80 mutant protein coding sequence encodes a human CD80 mutant protein that comprises at least one of 80V, 80tm and 80ct and is free of all or part of the CD80 C region; wherein said CD80 mutant that is free of all or part of the CD80 C region comprises either 80V or 86ct or both and optionally comprises one or more of 86C, 80tm, 86tm, 80ct and 86ct wherein: 80V is the variable domain of human CD80; 86V is the variable domain of a human CD86; 86C is the C domain of human CD86; 80tm is the transmembrane region of human CD80; 86tm is the transmembrane region of a human CD86; 80ct is the cytoplasmic tail of human CD80; 86ct is the cytoplasmic tail of human CD86; wherein said human CD80 mutant protein possesses costimulatory activity of wild type CD80 and does not provide the negative signal associated with wild type human CD80 C region interactions with human CTLA4, and
b) a nucleic acid sequence comprising a coding sequence operably linked to regulatory elements, wherein said coding sequence that encodes said immunogen.
2. The method of claim 1 wherein said immunogen is an allergen.
3. The method of claim 1 wherein said immunogen is a pathogen antigen.
4. The method of claim 1 wherein said nucleic acid sequence that encodes a human CD80 mutant protein and said nucleic acid sequence that encodes the immunogen are part of same nucleic acid molecule.
5. The method of claim 4 wherein said nucleic acid molecule is a plasmid.
6. The method of claim 1 wherein said nucleic acid sequence that encodes a human CD80 mutant protein is part of a first nucleic acid molecule and said nucleic acid sequence that encodes the immunogen are part of a second nucleic acid molecule.
7. The method of claim 1 wherein said first nucleic acid molecule is a plasmid and said second nucleic acid molecule is a plasmid.
8. The method of claim 1 wherein said human CD80 mutant protein comprises part of human CD80 C region.
9. The method of claim 8 wherein said nucleic acid sequence that encodes a human CD80 mutant protein is part of one nucleic acid molecule and said nucleic acid sequence that encodes the immunogen are part of the same nucleic acid molecule.
10. The method of claim 9 wherein the nucleic acid molecule is a plasmid.
11. The method of claim 8 wherein said nucleic acid sequence that encodes a human CD80 mutant protein that comprises part of human CD80 C region is part of a first nucleic acid molecule and said nucleic acid sequence that encodes the immunogen are part of the second nucleic acid molecule.
12. The method of claim 11 wherein said first nucleic acid molecule is a plasmid and said second nucleic acid molecule is a plasmid.
13. The method of claim 1 wherein said human CD80 mutant protein comprises a human CD80 V region, a functional human CD80 μm and a human CD80 ct region, and is free of a functional C region by the absence of all or part of the a human CD80 C region.
14. The method of claim 13 wherein said nucleic acid sequence that encodes a human CD80 mutant protein is part of one nucleic acid molecule and said nucleic acid sequence that encodes the immunogen are part of the same nucleic acid molecule.
15. The method of claim 14 wherein the nucleic acid molecule is a plasmid.
16. The method of claim 13 wherein said nucleic acid sequence that encodes a human CD80 mutant protein is part of a first nucleic acid molecule and said nucleic acid sequence that encodes the immunogen are part of the second nucleic acid molecule.
17. The method of claim 16 wherein said first nucleic acid molecule is a plasmid and said second nucleic acid molecule is a plasmid.
18. The method of claim 1 wherein the composition is administered into skin tissue.
19. The method of claim 1 wherein the composition is administered intramuscularly.
20. The method of claim 13 wherein the composition is administered into skin tissue.
21. The method of claim 13 wherein the composition is administered intramuscularly.